Skip to main content

Table 4 Relationship between COX-2 and MDR1/P-gp (detected with C219 or JSB-1 antibodies) expression and clinicopathologic factors

From: Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

Characteristics No. of patients (%)
  COX-2 positive COX-2 negative P value Chi2 test C219 high (IRS 4–12) C219 low (IRS 0–3) P value Chi2 test JSB-1 high (IRS 4–12) JSB-1 low (IRS 0–3) P value Chi2 test
pT          
   1 8 (8) 9 (9)   7 (7) 10 (10)   8 (8) 9 (9)  
   2 37 (36) 49 (47)   35 (34) 51 (49)   36 (35) 50 (48)  
   4 1 (1) 0 (0) 0.4954 1 (1) 0 (0) 0.7869 1 (1) 0 (0) 0.6306
pN          
   0 10 (10) 19 (18)   11 (11) 18 (17)   11 (11) 18 (17)  
   1 36 (35) 39 (37) 0.2117 32 (31) 43 (41) <0.001 34 (33) 41 (39) <0.001
Stage          
   I 1 (1) 2 (2)   1 (1) 2 (2)   1 (1) 2 (2)  
   IIa 16 (15) 24 (23)   16 (15) 24 (23)   17 (16) 23 (22)  
   IIb 28 (27) 32 (31)   25 (24) 35 (34)   29 (28) 31 (30)  
   IIIb 1 (1) 0 (0) 0.6628 1 (1) 0 (0) 0.5915 1 (1) 0 (0) 0.5874
Grade          
   2 26 (25) 45 (43)   25 (24) 46 (44)   26 (25) 45 (43)  
   3 20 (19) 13 (13) 0.0135 18 (17) 15 (14) <0.001 19 (18) 14 (13) < 0.001
Menopause          
   Praemenopausal 12 (12) 18 (17)   13 (13) 17 (16)   14 (13) 16 (15)  
   Postmenopausal 34 (33) 40 (38) 0.4553 30 (30) 44 (42) 0.8307 31 (30) 43 (41) 0.9703
  1. COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score.